Close Menu

NEW YORK – Cepheid said today that the US Food and Drug Administration has cleared its Xpert BCR-ABL Ultra test for monitoring disease burden in patients with chronic myeloid leukemia.

The in vitro diagnostic test can deliver accurate molecular results from whole blood samples in less than three hours, the company said in a statement. Measuring BCR-ABL gene transcript levels can indicate how well treatment for CML patients is working and predict relapses.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The New York Times reports on an effort to address in high school biology classes misconceptions regarding race and genetics.

60 Minutes speaks with Harvard's George Church about tackling the effects of aging and more.

In PLOS this week: rare alterations in Timothy syndrome, analysis of twins' gut microbiomes, and more.

GenomeWeb reports that Veritas Genetics is suspending its US operations.